Our use of cookies
We would like to use necessary cookies to perform the basic functions of this website. Such strictly necessary cookies do not require your consent and are therefore always active. We would also like to set analytical cookies and advertising cookies that help us make improvements by measuring how you use our website. Both the analytical cookies and advertising cookies require your consent and are therefore called “optional cookies”. Detailed information about the use of cookies and how you can control your consent for optional cookies can be found in our Cookie Policy and Privacy Policy.

Accept all optional cookies Reject all optional cookies
Hello! We use cookies to help improve your experience of our website. With your consent, statistical and analytical cookies may also be used on this website. If you agree to the use of these additional cookies, please mark your choice:

Menu

Back to news

MGI Launches Overseas Production Line of DNBSEQ-G400* Sequencer in Latvia

08.05.2023

Offline

Riga, Latvia, MGI

JrMJoPeITU1voELNW4J6Jw6qfQ5F4YeoODKXm04o.jpg
In a significant move that further solidifies its commitment to advancing life science technology, MGI Tech Co., Ltd. ("MGI") is proud to announce the launch of its overseas production line in Latvia. Under the subsidiary name LATVIA MGI TECH, SIA ("MGI Latvia"), the company has established a large-scale facility in Riga to assemble and produce the state-of-the-art DNBSEQ-G400* gene sequencing instruments and HotMPS** reagents. This strategic expansion marks a significant milestone for MGI's growth in Europe, enabling the company to provide cutting-edge solutions for its customers and partners in the region.

MGI's Expansion in Europe

Europe has always been at the forefront of technology and innovation, making it a key market for MGI. By launching its production line in Latvia, MGI aims to leverage the region's technological prowess and establish a strong foothold in Europe's life science sector. The facility in Riga will serve as MGI's largest regional hub in Europe, enabling efficient production, assembly, and distribution of the DNBSEQ-G400* sequencers and HotMPS** reagents.

A Milestone Achievement

During the official opening ceremony, MGI unveiled the first DNBSEQ-G400* instrument produced at the Latvia site. This momentous occasion represents a significant step forward for MGI's European business development. As the company gradually increases its production capacity, a dedicated team of engineers in Latvia will provide ongoing support for production and quality control. Additionally, MGI Latvia will offer comprehensive aftersales support and maintenance services to ensure the seamless operation of the sequencing instruments.

MGI Latvia's Contributions to Research and Development

Since its establishment in 2019, MGI Latvia has emerged as a dynamic hub for research and development, production, logistics, and specialized training. With a remarkable investment exceeding 20 million euros, MGI Latvia is the largest foreign investment in the biotechnology sector in Latvia and the Baltics to date. The facility spans 7,000 square meters and features a Global Product Application Demo Centre and a state-of-the-art Customer Experience Center, which opened last year to showcase MGI's latest technologies. In addition to production activities, MGI Latvia has successfully collaborated with local and regional partners on numerous funded research programs, including Horizon 2020.

DNBSEQ-G400*: Advancing DNA Sequencing Technology

The DNBSEQ-G400* is a versatile, medium throughput benchtop sequencer that empowers researchers with its flexible sequencing modes. With its new Flow Cell system, the G400* enables users to run one or two flow cells, offering various read length options from SE50 to SE400 or PE300. The instrument incorporates optimized optical and biochemical systems, accelerating the sequencing process and delivering a streamlined user experience.

HotMPS**: Enhancing Sequencing Chemistry

Designed specifically for use with the DNBSEQ-G400*, the innovative HotMPS** sequencing chemistry complements commonly used library preparation methods. Leveraging MGI's core DNBSEQ™ technology and the combinatorial Probe Anchor Synthesis (cPAS) technology, HotMPS** achieves breakthroughs in nucleotides and enzymes used in the sequencing process. This cutting-edge chemistry ensures low error rates, minimal duplication, and negligible index hopping, enhancing the accuracy and reliability of sequencing results.

  • MGI Tech Co., Ltd. establishes an overseas production line in Latvia for the assembly of DNBSEQ-G400* gene sequencing instruments and HotMPS** reagents.
  • The facility in Riga, Latvia, serves as MGI's largest regional hub in Europe and enables efficient production, assembly, and distribution of the advanced sequencing technology.
  • The launch of the production line marks a significant step in MGI's European business development, expanding its capacity to provide cutting-edge solutions and support for customers and partners in the region.


Conclusion

MGI's launch of its overseas production line in Latvia represents a significant milestone in the company's mission to advance life science tools and technologies. By expanding its presence in Europe, MGI is well-positioned to serve its customers and partners with real-time, comprehensive, and innovative solutions. The establishment of the Latvia facility, alongside the production of the DNBSEQ-G400* sequencers and HotMPS** reagents, underscores MGI's dedication to driving scientific innovation in DNA sequencing. As demand for advanced genomic solutions continues to grow, MGI remains committed to expanding its production capacity and enhancing its presence in Europe to meet the evolving needs of the scientific community.

  • Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, Spain, UK, Sweden, Italy, Czech Republic, Switzerland, and Hong Kong (CoolMPS is available in Hong Kong).
  • For Research Use Only. Not for use in diagnostic procedures (except as specifically noted).
    ** This sequencing reagent is only available in selected countries.
 

About MGI

MGI Tech Co., Ltd. (MGI) is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production, and sales of sequencing instruments***, reagents***, and related products to support life science research, agriculture, precision medicine, and healthcare. MGI's mission is to develop and promote advanced life science tools for future healthcare. As of December 2021, MGI has a footprint that spans across more than 80 countries and regions, serves over 1,300 international users, and employs more than 2,050 professionals globally, around 35% of which are R&D personnel. For more information, please visit the mgi-tech.eu or connect on Twitter, LinkedIn, or YouTube.
 

In, or YouTube.

Writen by: Shafraz Jeal

More news

All news and events
T5861CsYLvEtmup25T3Scvtr6rv706sIKSH4RpAL.png

26.07.24

MGI and HKBU Collaborate on Advanced Sequencing Technology to Combat Doping in Sports

Advanced Sequencing Tech Battles Doping at Paris 2024 Olympics

Read more
EvHOhGq6bG0eLlWGbKsQjc2bF8ig81LJ9jbf4wMe.png

18.07.24

Elite Controllers: Do their genomes hold the key to curing HIV?

South Africa is advancing HIV research using MGI’s sequencing tools to study "HIV elite controllers" - A rare group of individuals whose immune systems can suppress infection. Scientists from the SAMRC and UKZN are revealing the answer to the natural control of HIV infection leading to new therapies and improved health outcomes.

Read more
UWtnzW5ocacnW2qhUiwynHs7UVLE4UOImBJixseh.webp

11.07.24

MGI Tech and Predica Diagnostics Team Up for Precision RNA Sequencing in Oncology

MGI Tech and Predica Diagnostics partner to develop affordable targeted RNA sequencing tests for oncology, enhancing early cancer detection and personalized treatment.

Read more